Industry Post-Stenting Antiplatelet Trial Gains $1.5 Million Boost From FDA
This article was originally published in The Pink Sheet Daily
Study aims to identify optimum duration of anti-clotting drugs for stent patients; enrollment targeted at 20,000 patients.
You may also be interested in...
FDA seems more concerned about mortality than most academics following trial of dual antiplatelet therapy after stenting; AstraZeneca sees potential opening for Brilinta.
Lilly/Daiichi Sankyo's prasugrel has carefully constructed label to control risk of bleeding - but it also includes a pharmacogenetic argument that Effient works in clopidogrel non-responders.
FDA, along with the four major drug-eluting stent manufacturers and four antiplatelet drug firms, are months away from launching an unprecedented $100 million, 20,000-patient trial to determine the optimum duration of dual antiplatelet therapy with drug-eluting stents